Regulatory T cells induced by B cells: a novel subpopulation of regulatory T cells by Chien-Hui Chien, Bor-Luen Chiang

Subjects: Get full text

Mitogen-Activated Protein Kinase Inhibitors and T-Cell-Dependent Immunotherapy in Cancer by Sandeep Kumar, Daniel R. Principe, Sunil Kumar Singh, Navin Viswakarma, Gautam Sondarva, Basabi Rana, Ajay Rana

Subjects: Get full text

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle by Maria A.V. Marzolini, Sergio A. Quezada, Karl S. Peggs

Subjects: Get full text

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer by Said Dermime, Said Dermime, Said Dermime, Maysaloun Merhi, Maysaloun Merhi, Taha Merghoub, Taha Merghoub, Taha Merghoub, Taha Merghoub

Subjects: Get full text

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition by Jared M. Newton, Aurelie Hanoteau, Hsuan-Chen Liu, Angelina Gaspero, Falguni Parikh, Robyn D. Gartrell-Corrado, Thomas D. Hart, Damya Laoui, Jo A. Van Ginderachter, Neeraja Dharmaraj, William C. Spanos, Yvonne Saenger, Simon Young, Andrew G. Sikora

Subjects: Get full text

The Anticancer Power of the Immune System – New Perspectives for Patients with Triple-Negative Breast Cancer by Katarzyna Rygiel

Subjects: Get full text

Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors by Tamir Baram, Nofar Erlichman, Maya Dadiani, Nora Balint-Lahat, Anya Pavlovski, Tsipi Meshel, Dana Morzaev-Sulzbach, Einav Nili Gal-Yam, Iris Barshack, Adit Ben-Baruch

Subjects: Get full text

Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database by Ye Xu, Cilin Yan, Ying Zhao, Dandan Li, Mingxing Guo, Xiangli Cui

Subjects: Get full text

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States by Rajwanth Veluswamy, Fred R. Hirsch, Emanuela Taioli, Juan Wisnivesky, Ross Strauss, Douglas Harrough, Boxiong Tang, Gisoo Barnes

Subjects: Get full text

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal by Zhenqing Wang, Liang Chen, Yiqun Ma, Xilei Li, Annan Hu, Huiren Wang, Wenxing Wang, Xiaomin Li, Bo Tian, Jian Dong

Subjects: Get full text

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events by Remo Poto, Teresa Troiani, Gjada Criscuolo, Gjada Criscuolo, Giancarlo Marone, Fortunato Ciardiello, Carlo Gabriele Tocchetti, Gilda Varricchi, Gilda Varricchi, Gilda Varricchi, Gilda Varricchi

Subjects: Get full text

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor M... by Muhammad Joan Ailia, Jeong Heo, So Young Yoo

Subjects: Get full text

Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors by Patrícia S. Sobral, Vanessa C. C. Luz, João M. G. C. F. Almeida, Paula A. Videira, Florbela Pereira

Subjects: Get full text

Recent Advances in the Treatment of Breast Cancer by Christy W. S. Tong, Mingxia Wu, William C. S. Cho, Kenneth K. W. To

Subjects: Get full text

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC) by Che-Wei Wang, Pulak Kumar Biswas, Atikul Islam, Mu-Kuan Chen, Pin Ju Chueh

Subjects: Get full text

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study by Na Li, Yong Feng, XiaoLing Chen, Ye Li, Chengmiao Zhang, Yin Yin

Subjects: Get full text

Radiotherapy combined with anti-PD-1 and TKI for primary cardiac angiosarcoma considering the joint assessment of TLSs and PD-L1: a case report by Shuzhe Deng, Xinxin Yang, Lin He, Qian Zhang, Chunbo Zhao, Hongxue Meng

Subjects: Get full text

Advances in cancer immunotherapy 2019 – latest trends by Stephan Kruger, Matthias Ilmer, Sebastian Kobold, Bruno L. Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard W. Renz, Jan G. D’Haese, Hans Schloesser, Volker Heinemann, Marion Subklewe, Stefan Boeck, Jens Werner, Michael von Bergwelt-Baildon

Subjects: Get full text

Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer by Fadhl Alshaebi, Mohammed Safi, Yousif A. Algabri, Mahmoud Al-Azab, Abdullah Aldanakh, Mohammed Alradhi, Alariqi Reem, Caiqing Zhang

Subjects: Get full text

FR -Inmunoterapia en el carcinoma de células de Merkel by M.F. García-Gil, M. Ramírez-Lluch, M.A. Concellón-Doñate

Subjects: Get full text